Marrone Bio Innovations, Inc.

NasdaqCM:MBII Stock Report

Market Cap: US$145.6m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Marrone Bio Innovations Future Growth

Future criteria checks 2/6

Key information

71.8%

Earnings growth rate

77.0%

EPS growth rate

Chemicals earnings growth15.3%
Revenue growth rate25.0%
Future return on equityn/a
Analyst coverage

Low

Last updatedn/a

Recent future growth updates

Recent updates

Marrone Bio Innovations shareholders approve merger deal with Bioceres Crop Solutions

Jul 11

Time To Worry? Analysts Are Downgrading Their Marrone Bio Innovations, Inc. (NASDAQ:MBII) Outlook

Aug 21
Time To Worry? Analysts Are Downgrading Their Marrone Bio Innovations, Inc. (NASDAQ:MBII) Outlook

Marrone Bio Innovations, Inc. (NASDAQ:MBII) Is Expected To Breakeven In The Near Future

Apr 08
Marrone Bio Innovations, Inc. (NASDAQ:MBII) Is Expected To Breakeven In The Near Future

Is Marrone Bio Innovations (NASDAQ:MBII) Using Too Much Debt?

Mar 13
Is Marrone Bio Innovations (NASDAQ:MBII) Using Too Much Debt?

What Kind Of Investors Own Most Of Marrone Bio Innovations, Inc. (NASDAQ:MBII)?

Feb 15
What Kind Of Investors Own Most Of Marrone Bio Innovations, Inc. (NASDAQ:MBII)?

Marrone Bio Innovations (NASDAQ:MBII) Shareholders Have Enjoyed A 75% Share Price Gain

Jan 25
Marrone Bio Innovations (NASDAQ:MBII) Shareholders Have Enjoyed A 75% Share Price Gain

When Will Marrone Bio Innovations, Inc. (NASDAQ:MBII) Turn A Profit?

Jan 04
When Will Marrone Bio Innovations, Inc. (NASDAQ:MBII) Turn A Profit?

Does Marrone Bio Innovations (NASDAQ:MBII) Have A Healthy Balance Sheet?

Dec 09
Does Marrone Bio Innovations (NASDAQ:MBII) Have A Healthy Balance Sheet?

Marrone Bio Innovations, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 10

Earnings and Revenue Growth Forecasts

NasdaqCM:MBII - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202490N/AN/AN/A1
12/31/202371-4N/AN/A2
12/31/202256-16N/AN/A3
3/31/202244-21-15-13N/A
12/31/202144-17-12-10N/A
9/30/202141-15-16-14N/A
6/30/202140-17-16-14N/A
3/31/202140-16-17-15N/A
12/31/202038-20-18-16N/A
9/30/202037-26-15-14N/A
6/30/202035-36-21-18N/A
3/31/202030-40-22-20N/A
12/31/201929-37-22-21N/A
9/30/201928-33-20-19N/A
6/30/201927-21-15-15N/A
3/31/201926-19-18-17N/A
12/31/201821-20-20-19N/A
9/30/201819-22-24-23N/A
6/30/201818-26-27-26N/A
3/31/201818-29-24-23N/A
12/31/201718-31-22-21N/A
9/30/201718-31-21-20N/A
6/30/201717-30-21-21N/A
3/31/201716-29-22-22N/A
12/31/201614-31-25-24N/A
9/30/201613-34-26-26N/A
6/30/201612-37-30-29N/A
3/31/201610-41-35-35N/A
12/31/201510-44N/A-36N/A
9/30/20159-49N/A-38N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MBII is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MBII is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MBII is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MBII's revenue (25% per year) is forecast to grow faster than the US market (7.9% per year).

High Growth Revenue: MBII's revenue (25% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if MBII's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/07/13 11:37
End of Day Share Price 2022/07/12 00:00
Earnings2022/03/31
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Marrone Bio Innovations, Inc. is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nathan WeinsteinAegis Capital Corporation
Benjamin KalloBaird
Benjamin KlieveB. Riley Wealth